Comparative Pharmacology
Head-to-head clinical analysis: GRAFAPEX versus QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRAFAPEX versus QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE.
GRAFAPEX vs QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GRAFAPEX is a monoclonal antibody that binds to and inhibits the activity of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
Quinapril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion; hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
10-20 mg orally once daily, maximum 40 mg per day.
Initial: 10/12.5 mg (quinapril/hydrochlorothiazide) orally once daily. Titrate based on response to a maximum of 40/25 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10-14 hours); clinical context: dosing interval recommended every 24 hours to maintain therapeutic levels
Quinaprilat terminal half-life ~25 hours (effective half-life ~12 hours); hydrochlorothiazide ~6-15 hours (increased in renal impairment).
Renal: 60% as unchanged drug; biliary/fecal: 30%; minor metabolism: 10%
Renal excretion of quinaprilat (active metabolite) ~50-60% unchanged; hydrochlorothiazide ~70% unchanged. Biliary/fecal elimination accounts for <10% for both components.
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor